Loblaw, a prominent grocery retailer, reported increased profits in the second quarter, driven by strong performance in its discount chains No Frills and Maxi. The company highlighted significant sales growth in its pharmacy unit, attributing it to the impact of generic GLP-1 weight loss drugs.
In its financial results for the quarter ending June 20, Loblaw disclosed revenue surpassing $15.3 billion, marking a four percent increase from the previous quarter. Profit available to common shareholders also rose by five percent to $751 million.
The company noted a 1.6 percent rise in same-store sales for its core retail food business and a substantial 4.6 percent gain in same-store sales for its drug retail unit, primarily fueled by a 7.5 percent increase in pharmacy and health-care services.
During a conference call with stock market analysts, Loblaw’s chief financial officer, Richard Dufresne, emphasized the positive impact of generic GLP-1 drugs on the company’s pharmacy performance. He mentioned that lower generic drug pricing is being balanced by higher volumes, leading to expectations of increased revenue, gross profit dollars, and gross margin rate.
The approval of Canada’s first generic semaglutide injection by Health Canada in late April has notably boosted sales of GLP-1 drugs for Loblaw, with a reported 40 percent increase year-to-date.
Chief executive Per Bank highlighted a shift in consumer behavior towards buying more frozen vegetables over fresh produce due to inflation, with frozen veg sales growing by over five percentage points at No Frills and Maxi stores.
Dufresne reiterated Loblaw’s strong market positioning in the face of food price inflation, emphasizing the company’s continued focus on value for customers. Despite the challenging market conditions, Loblaw remains competitive and has seen a six percent increase in its shares year-to-date.
Overall, Loblaw’s performance in the second quarter reflects its strategic focus on driving sales through its discount chains and adapting to changing consumer preferences amidst economic challenges.